Nymox Reports on Symposium and Panel Discussion on NX-1207 at American Urological Association Annual Meeting
May 06 2013 - 9:00AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report
on the presentation on NX-1207 drug studies at a high-level
symposium and panel discussion held at the Annual Meeting of the
American Urological Association in San Diego, CA between 3:00 and
4:00 pm PDT on Sunday. The well-attended symposium highlighted the
ongoing clinical development program for NX-1207 for the treatment
of benign prostatic hyperplasia (BPH) and featured expert panel
discussions on the new therapy. The Company is pleased to report
that the pivotal U.S. Phase 3 trials of NX-1207 for BPH, NX02-0017
and NX02-0018, have now completed enrollment.
The symposium, "Clinical studies of NX-1207: Phase 3 Injectable
for BPH (Phase 2 for Prostate Cancer)," was chaired by Ronald F.
Tutrone Jr., MD, FACS of Towson, MD. The other panel members at the
Symposium were Dr. Mohamed Bidair of San Diego CA, Dr. Susan J.
Kalota of Tucson AZ, Dr. Franklin D. Gaylis of San Diego CA, Dr.
Sheldon Freedman of Las Vegas NV, Dr. Eugene Dula of Tarzana CA,
and Dr. Michael T. Gambla of Columbus OH.
According to Dr. Tutrone, "I will be excited to see the results
from the Phase 3 trials. I feel that NX-1207 has the potential to
be a game changer in BPH and to dramatically improve the quality of
life for men that suffer from BPH."
Dr. Dula said that NX-1207 is "the most innocuous and quick
therapy for BPH. It delivers the medicine where you need it."
Dr. Kalota said that in her experience "NX-1207 is easy to
inject and well tolerated and frequently produces excellent
results."
Dr. Bidair said that NX-1207 was "extremely well
tolerated." He added that it took "less time to perform the
procedure than to get the patient ready on the table."
Dr. Gaylis was of the opinion that NX-1207 was "an attractive
novel therapy for BPH and for local low risk prostate cancer."
Dr. Freedman said "I think that NX-1207 is an out-of-the-box
treatment like nothing else. There has never been an easier
treatment for this affliction."
Dr. Gambla said that NX-1207 "is the least minimally invasive
therapy I am aware of."
The first pivotal Phase 3 U.S. study of NX-1207 for BPH
(NX02-0017) completed enrollment in November 2012; the second
(NX02-0018) in April 2013. Overall, NX-1207 is being evaluated in
six large studies, including two safety reinjection studies
(NX02-0020 and NX02-0022), a European pivotal study (ERNEST) being
conducted by Recordati S.p.A, the Company's European partner, and a
U.S. Phase 2 prostate cancer study (NX03-0040). The Company
previously successfully completed four Phase 1 and Phase 2 clinical
trials of NX-1207 for BPH as well as over ten additional follow-up
studies.
The Symposium presented further scientific data on the results
of immunological testing of patients who received NX-1207. Current
data shows no evidence of antibody formation against NX-1207 or
hypersensitivity to NX-1207 in men. In addition, updated
pharmacokinetic studies have provided further evidence to
corroborate the absence of systemic toxicities for NX-1207. To
date, the safety profile of NX-1207 has been excellent.
NX-1207 is a novel patented drug developed by Nymox which is
currently in late stage Phase 3 trials for benign prostatic
hyperplasia (BPH) and Phase 2 for localized prostate cancer.
NX-1207 is injected into the sector of prostate to be treated by a
urologist in a clinic setting. The procedure does not require
catheterization, anesthesia, or sedation, takes only a few minutes
and involves little or no pain or discomfort to the patient. In
multi-center U.S. clinical trials for BPH to date, a single dose of
NX-1207 has been found to produce on average symptomatic
improvements about double that reported for currently approved BPH
drugs without causing the sexual or cardiovascular side effects
associated with those drugs. Follow-up studies have shown evidence
of long lasting benefit with a significant proportion of men who
received a single dose reporting improvement in BPH symptoms
without other treatments for up to 7½ years.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024